DUSP9 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-mediated gene disruption model designed to abolish DUSP9 function in a polyclonal population of human HAP1 cells. This cell product provides a heterogeneous pool of edited cells, each carrying a targeted disruption of the DUSP9 locus generated by CRISPR/Cas9 without clonal selection. DUSP9 encodes a dual-specificity phosphatase that selectively dephosphorylates phosphothreonine and phosphotyrosine residues within MAP kinases, and its inactivation creates a powerful tool for studying negative regulation of MAPK cascades.
The host cell line, HAP1, is a near-haploid chronic myeloid leukemia line derived from KBM-7 cells. Its near-haploid karyotype simplifies genetic manipulation and phenotypic analysis, as only one allele needs to be disrupted to achieve functional knockout. Originally established from a leukemia patient, HAP1 retains cancer-relevant signaling pathways and is widely used in functional genomics studies. This genetic background makes it particularly suitable for dissecting oncogenic signaling networks where MAPK dysregulation is common.
DUSP9 functions as a key negative regulator of MAPK pathways. It directly dephosphorylates and inactivates ERK1/2 (MAPK1/3), JNK (MAPK8/9/10), and p38 (MAPK11/12/13/14) in response to extracellular stimuli. Transcriptionally regulated by CREB and AP-1 downstream of MAPK signaling, DUSP9 is also controlled by insulin. Its activity modulates proliferation, differentiation, survival, and metabolism. Representative pathway components include RAS, RAF, and MEK, which relay signals to ERK, JNK, and p38, ultimately regulated by DUSP9.
In the HAP1 leukemia cell context, DUSP9 loss-of-function facilitates investigation of MAPK hyperactivation in cancer. Chronic myeloid leukemia cells often exhibit altered MAPK signaling, and DUSP9 disruption can reveal its tumor-suppressive or oncogenic roles depending on context. This model enables studies on how DUSP9-mediated dephosphorylation affects cell cycle progression, apoptosis sensitivity, and drug response. Moreover, the near-haploid background allows clean interpretation of signaling dynamics without compensation from a second allele, enhancing the robustness of pathway analysis.
Researchers can employ DUSP9 knockout HAP1 polyclonal cells in a variety of experimental workflows. Functional validation of DUSP9 loss can be assessed through western blotting for phospho-ERK, phospho-JNK, and phospho-p38, RT-qPCR for DUSP9 transcript levels, and co-immunoprecipitation of MAPK1/3 interactions. The model supports proliferation, colony formation, and apoptosis assays to evaluate cancer cell behavior, as well as MAPK reporter assays and drug sensitivity screens for therapeutic target identification. In metabolic disease research, insulin signaling studies can be conducted to link DUSP9 to type 2 diabetes mechanisms. For additional product details or technical support, please contact Ascent Research.
